CytomX Announces Upcoming Poster Presentations at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference

Monday, October 16, 2017 5:00 PM UTC

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2017 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced that preclinical results will be presented at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference will take place October 26-30 in Philadelphia.

Abstract Information:

Title:	EGFR-CD3 bispecific Probody therapeutic induces tumor regressions and increases maximum tolerated dose >60 fold in preclinical studies
Session Category:	EGFR/Her2
Date:	Saturday, October 28
Time:	Poster Session A: 12:30 p.m. – 4:00 p.m.
Location:	Hall E, Pennsylvania Convention Center
Abstract:	A164

The EGFR-CD3 bispecific Probody therapeutic poster will also be included in the Spotlight on Proffered Papers session starting at 10:50 a.m. on Friday, October 27 in the Terrance Ballroom, 400 level.

Title:	Optimizing a CD71-targeting Probody drug conjugate (PDC) for activity in multiple solid tumor and lymphoma models and for tolerability in nonhuman primates
Session Category:	Therapeutic Agents: Biological
Date:	Sunday, October 29
Time:	Poster Session B: 12:30 p.m. – 4:00 p.m.
Location:	Hall E, Pennsylvania Convention Center
Abstract:	B116

Title:	A multi-analyte HPLC-MS/MS approach to assessing exposure of a Probody drug conjugate (PDC) in preclinical studies
Session Category:	Therapeutic Agents: Biological
Date:	Sunday, October 29
Time:	Poster Session B: 12:30 p.m. – 4:00 p.m.
Location:	Hall E, Pennsylvania Convention Center
Abstract:	B103

Title:	Nonclinical safety evaluation of two distinct second generation variants of anti-CTLA4 monoclonal antibody, ipilimumab, in monkeys
Session Category:	Therapeutic Agents: Biological
Date:	Sunday, October 29
Time:	Poster Session B: 12:30 p.m. – 4:00 p.m.
Location:	Hall E, Pennsylvania Convention Center
Abstract:	LB-B33

About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of Probody™ therapeutics. Probody therapeutics exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1 and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer Center and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.

Media Contact:
Spectrum
Amir Khan
[email protected]
212-899-9730

Investor Contact:
Trout Group
Pete Rahmer
[email protected]
646-378-2973

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

CytomX Announces Upcoming Poster Presentations at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference

Editor's Picks

Welcome to EconoTimes